As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.
|Videos|May 19, 2023
The Burden of Treatment Resistant Depression
Ryan J. Wakim, MD, DFAPA, explores the causes and diagnostic criteria for treatment resistant depression. He also discusses the importance of comprehensive assessment and personalized approaches to care.
Advertisement
Advertisement
Related to this article
Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Advertisement
Advertisement
Trending on HCPLive
1
The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH
2
Anti-Alpha-Gal Antibodies Block IgE Binding in Alpha-Gal Syndrome
3
FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome
4
Zilurgisertib Receives FDA Approval for FOP in Patients 12 and Older
5